Keywords: ARIAD Pharma, Ridaforolimus, Merck & Co, Sarcoma, Ponatinib, Leukemia

ARIAD rises on decision to co-promote ridaforolimus with Merck & Co on US approval

Article | 21 March 2011

Print This

ARIAD Pharmaceuticals (Nasdaq: ARIA) saw its shares jump 5.5% to $5.93 when it revealed that it has opted to exercise its option ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in